Jun 08, 2023 / 02:00PM GMT
Maurice Thomas Raycroft - Jefferies LLC, Research Division - Equity Analyst
Hi, everyone. My name is Maury Raycroft, and I'm one of the biotech analysts at Jefferies. I am happy to introduce our guests today, Richard Paulson, the President and CEO; and Reshma Rangwala, the CMO of Karyopharm Therapeutics. Thanks so much for joining us today.
Richard A. Paulson - Karyopharm Therapeutics Inc. - President, CEO & Director
Thanks for having us, Maury.
Maurice Thomas Raycroft - Jefferies LLC, Research Division - Equity Analyst
And we're going to do a fireside chat format. So maybe for those who are new to the story, if you can provide a 1-minute intro to Karyopharm.
Richard A. Paulson - Karyopharm Therapeutics Inc. - President, CEO & Director
Sure. I mean Karyopharm was founded in 2008 as an innovation and patient-focused company really driving a first-in-class focus on the selective inhibition of nuclear exports and developing an all-oral medicine, which inhibits XPO1. And
Karyopharm Therapeutics Inc at Jefferies Healthcare Conference Transcript
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot